In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
Positive results from the Phase III program comprising the REVISIT and ASSEMBLE studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) have been released by US pharma giant Pfizer. 1 June 2023
Biotechnology
Positive clinical progress with donidalorsen, a late-stage investigational prophylactic therapy for hereditary angioedema (HAE), were announced this morning by US RNA-targeted drug developer Ionis Pharmaceuticals. 1 June 2023
Biotechnology
Swiss contract development and manufacturing organization (CDMO) Lonza today announced it has acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugate (ADCs). 1 June 2023
Biotechnology
As anticipated, Pfizer as secured US Food and Drug Administration approval for its bivalent RSV vaccine, targeting disease caused by RSV in people over the age of 60. 1 June 2023
Biotechnology
Dutch biotech firm Pharming said today that it has entered into a definitive agreement with Swiss pharma giant Novartis to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis. 1 June 2023
Pharmaceutical
As the crowds descend on Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO), The Pharma Letter interviews Eisai chief medical officer Kirk Shepard about his firm’s progress in oncology. 1 June 2023
Pharmaceutical
Following a mixed advisory panel vote in late April, the US Food and Drug Administration FDA) said yesterday that it has approved UK pharma major AstraZeneca’s Lynparza (olaparib). 1 June 2023
Biotechnology
Industry analyst GlobalData has forecast rapid uptake of AbbVie’s Rinvoq (upadacitinib) following US Food and Drug Administration approval. 1 June 2023
Pharmaceutical
Swedish immunology company InDex Pharmaceuticals InDex Pharmaceuticals has signed a license agreement with the Japanese subsidiary of Viatris to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. 1 June 2023
Biotechnology
Today, Daniel Cameron, Attorney General for the US State of Kentucky, announced that the State will take $42 million from its portion of the Opioid Settlement Funds and use it for psychedelic research, specifically ibogaine for opioid addiction. 31 May 2023
Pharmaceutical
This year’s meeting of the American Society of Clinical Oncology (ASCO) kicks off on Friday, with the highly anticipated plenary session taking place on Sunday. 31 May 2023
Pharmaceutical
Shares of US biotech Amylyx Pharmaceuticals fell more than 3% by close of trading Tuesday and a further 2.2% to $23.51 in pre-market activity today, after it said that a European regulatory panel had taken a negative view on its amyotrophic lateral sclerosis (ALS) treatment 31 May 2023
Pharmaceutical
In the runup to this year’s meeting of the American Society of Clinical Oncology (ASCO), drugmakers around the world are lifting the curtain on the data they plan to present at the event. 31 May 2023
Biotechnology
French pharma major Sanofi has presented new data at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrating that frexalimab, the firm’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase II trial of patients with relapsing multiple sclerosis (RMS). 31 May 2023
Pharmaceutical
Chinese artificial intelligence company XtalPi has agreed terms for a $250 million collaboration with Eli Lilly. 31 May 2023
Biotechnology
Belgium’s largest drugmaker UCB will present new long-term 52-week data from three Phase III studies of bimekizumab at the 2023 meeting of the European Congress of Rheumatology (EULAR). 31 May 2023
Biotechnology
US pharma giant Pfizer’s proposed $43 billion ($229 per share) acquisition of Seagen has won approval from the latter’s shareholders. 31 May 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk recently announced that the starter doses of its weight-management drug Wegovy (semaglutide) would be limited in the USA until September, in an effort to avoid supply shortages. 31 May 2023
Pharmaceutical
Given the emerging evidence on coronavirus SARS-CoV-2 variants and lessons learned from previous vaccine updates, international regulators have published a report highlighting the outcomes of their discussions on COVID-19 vaccines and the need for and strategy to update their composition. 31 May 2023
Biotechnology
Japanese drugmaker Chugai Pharmaceuticals has decided to invest over 50 billion yen ($356 million) in total for two new manufacturing facilities at the Utsunomiya plant. 31 May 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze